$163.73
1.25%
Nasdaq, Sep 02, 10:00 pm CET

Ligand Pharmaceuticals Incorporated Target price 2025 - Analyst rating & recommendation

Ligand Pharmaceuticals Incorporated Classifications & Recommendation:

Buy
92%
Hold
8%

Ligand Pharmaceuticals Incorporated Price Target

Target Price $168.81
Price $163.73
Potential
Number of Estimates 10
10 Analysts have issued a price target Ligand Pharmaceuticals Incorporated 2026 . The average Ligand Pharmaceuticals Incorporated target price is $168.81. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 12 Analysts recommend Ligand Pharmaceuticals Incorporated to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ligand Pharmaceuticals Incorporated stock has an average upside potential 2026 of . Most analysts recommend the Ligand Pharmaceuticals Incorporated stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 167.13 216.20
27.28% 29.36%
EBITDA Margin 33.49% 37.90%
1.15% 13.15%
Net Margin -2.41% 62.84%
106.07% 2,706.07%

10 Analysts have issued a sales forecast Ligand Pharmaceuticals Incorporated 2025 . The average Ligand Pharmaceuticals Incorporated sales estimate is

$216m
Unlock
. This is
15.26% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$232m 23.54%
Unlock
, the lowest is
$181m 3.28%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $167m 27.28%
2025
$216m 29.36%
Unlock
2026
$248m 14.89%
Unlock
2027
$292m 17.56%
Unlock
2028
$349m 19.69%
Unlock
2029
$416m 19.11%
Unlock
2030
$513m 23.28%
Unlock
2031
$626m 21.89%
Unlock
2032
$763m 22.00%
Unlock

7 Analysts have issued an Ligand Pharmaceuticals Incorporated EBITDA forecast 2025. The average Ligand Pharmaceuticals Incorporated EBITDA estimate is

$81.9m
Unlock
. This is
337.47% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$112m 499.84%
Unlock
, the lowest is
$41.9m 123.94%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $56.0m 28.75%
2025
$81.9m 46.37%
Unlock
2026
$141m 72.65%
Unlock
2027
$179m 26.67%
Unlock
2028
$223m 24.18%
Unlock
2029
$260m 16.65%
Unlock
2030
$306m 17.91%
Unlock

EBITDA Margin

2024 33.49% 1.15%
2025
37.90% 13.15%
Unlock
2026
56.95% 50.26%
Unlock
2027
61.37% 7.76%
Unlock
2028
63.67% 3.75%
Unlock
2029
62.36% 2.06%
Unlock
2030
59.64% 4.36%
Unlock

10 Ligand Pharmaceuticals Incorporated Analysts have issued a net profit forecast 2025. The average Ligand Pharmaceuticals Incorporated net profit estimate is

$136m
Unlock
. This is
279.09% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$142m 286.99%
Unlock
, the lowest is
$128m 269.01%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-4.0m 107.73%
2025
$136m 3,471.22%
Unlock
2026
$147m 8.49%
Unlock
2027
$168m 13.83%
Unlock
2028
$194m 15.57%
Unlock
2029
$212m 9.19%
Unlock
2030
$272m 28.57%
Unlock

Net Margin

2024 -2.41% 106.07%
2025
62.84% 2,706.07%
Unlock
2026
59.34% 5.57%
Unlock
2027
57.46% 3.17%
Unlock
2028
55.49% 3.43%
Unlock
2029
50.86% 8.34%
Unlock
2030
53.04% 4.29%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.22 7.00
107.51% 3,281.82%
P/E 23.39
EV/Sales 13.71

10 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast for earnings per share. The average Ligand Pharmaceuticals Incorporated EPS is

$7.00
Unlock
. This is
284.21% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$7.31 292.37%
Unlock
, the lowest is
$6.61 273.95%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.22 107.51%
2025
$7.00 3,281.82%
Unlock
2026
$7.59 8.43%
Unlock
2027
$8.64 13.83%
Unlock
2028
$9.99 15.63%
Unlock
2029
$10.91 9.21%
Unlock
2030
$14.03 28.60%
Unlock

P/E ratio

Current -43.09 194.89%
2025
23.39 154.29%
Unlock
2026
21.56 7.82%
Unlock
2027
18.94 12.15%
Unlock
2028
16.39 13.46%
Unlock
2029
15.01 8.42%
Unlock
2030
11.67 22.25%
Unlock

Based on analysts' sales estimates for 2025, the Ligand Pharmaceuticals Incorporated stock is valued at an EV/Sales of

13.71
Unlock
and an P/S ratio of
14.84
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 15.80 23.63%
2025
13.71 13.24%
Unlock
2026
11.93 12.96%
Unlock
2027
10.15 14.94%
Unlock
2028
8.48 16.45%
Unlock
2029
7.12 16.05%
Unlock
2030
5.77 18.89%
Unlock
2031
4.74 17.96%
Unlock
2032
3.88 18.03%
Unlock

P/S ratio

Current 17.10 18.12%
2025
14.84 13.24%
Unlock
2026
12.92 12.96%
Unlock
2027
10.99 14.93%
Unlock
2028
9.18 16.45%
Unlock
2029
7.71 16.05%
Unlock
2030
6.25 18.89%
Unlock
2031
5.13 17.96%
Unlock
2032
4.20 18.03%
Unlock

Current Ligand Pharmaceuticals Incorporated Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 28 2025
RBC Capital
Locked
Locked
Locked Aug 08 2025
Oppenheimer
Locked
Locked
Locked Jul 30 2025
Oppenheimer
Locked
Locked
Locked May 09 2025
Stifel
Locked
Locked
Locked Apr 10 2025
Benchmark
Locked
Locked
Locked Dec 23 2024
Barclays
Locked
Locked
Locked Dec 16 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 28 2025
Locked
RBC Capital:
Locked
Locked
Aug 08 2025
Locked
Oppenheimer:
Locked
Locked
Jul 30 2025
Locked
Oppenheimer:
Locked
Locked
May 09 2025
Locked
Stifel:
Locked
Locked
Apr 10 2025
Locked
Benchmark:
Locked
Locked
Dec 23 2024
Locked
Barclays:
Locked
Locked
Dec 16 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today